
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …

The FDA has released that GSK would be voluntarily recalling close to 600,000 of its Ventolin asthma inhalers across the …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

